Contemporary management of spasmodic dysphonia

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 12, Issue 6, 2004, Pages 543-548

  Sulica, Lucian ^a,b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b Department of Otolaryngology ^*  (United States)

Author keywords

Botulinum toxin; Denervation; Dystonia; DYT1 gene; Myoplasty; Spasmodic dysphonia; Thyroplasty

Indexed keywords

BENZODIAZEPINE; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE DERIVATIVE; LIDOCAINE;

ACUPUNCTURE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHONIA; DYSTONIA; GENETICS; HEALTH CARE; HUMAN; LARYNX; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SPASMODIC DYSPHONIA; SPEECH REHABILITATION; STANDARDIZATION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREMOR;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; VOCAL CORDS; VOICE DISORDERS;

EID: 9444256314     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moo.0000145959.50513.5e     Document Type: Review

References (45)

1. American Academy of Otolaryngology-Head and Neck Surgery: Policy Statement: Botulinum Toxin. Revised April 9, 1997; reaffirmed March 1, 1998. www.entlink.net/practice/rules/botox_treatment.cfm.
2. Blitzer A, Brin MF, Stewart CF: Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998, 108:1435-1441.
3. Schweinfurth JM, Billante M, Courey MS: Risk factors and demographics in patients with spasmodic dysphonia. Laryngoscope 2002, 112:220-223.
4. Cannifo MP, Johnson JP: Spastic dysphonia: a continuum disorder. J Commun Disord 1981, 14:215-223.
5. Cyrus CB, Bielamowicz S, Evans FJ, Ludlow CL: Adductor muscle activity abnormalities in abductor spasmodic dysphonia. Otolaryngol Head Neck Surg 2001, 124:23-30.
6. Lundy DS, Roy S, Xue JW, et al.: Spastic/spasmodic vs. tremulous vocal quality: motor speech profile analysis. J Voice 2004, 18:146-152.
7. Dedo HH: Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol 1976, 85:451-459.
8. Biller HF, Som ML, Lawson W: Laryngeal nerve crush for spastic dysphonia. Ann Otol Rhinol Laryngol 1979, 88:531-532.
9. Levine HL, Wood BG, Batza E, et al.: Recurrent laryngeal nerve section for spasmodic dysphonia. Ann Otol Rhinol Laryngol 1979, 88:527-530.
10. Fritzell B, Hammarberg B, Schiratzki H, et al.: Long-term results of recurrent laryngeal nerve resection for adductor spasmodic dysphonia. J Voice 1993, 7:172-178.
11. Aronson AE, De Santo LW: Adductor spastic dysphonia: three years after recurrent laryngeal nerve section. Laryngoscope 1983, 93:1-8.
12. Dedo HH, Izdebski K: Evaluation and treatment of recurrent spasticity after recurrent laryngeal nerve section: a preliminary report. Ann Otol Rhinol Laryngol 1984, 93:343-345.
13. Netterville JL, Stone RE, Rainey C, et al.: Recurrent nerve avulsion for treatment of spastic dysphonia. Ann Otol Rhinol Laryngol 1991, 100:10-14.
14. Schiratzki H, Fritzell B: Treatment of spasmodic dysphonia by means of resection of the recurrent laryngeal nerve. Acta Otolaryngol Suppl 1988, 449:115-117.
15. Blitzer A, Brin MF, Fahn S, et al.: Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 1986, 96:1300-1301.
16. Bressman SB: Dystonia update. Clin Neuropharmacol 2000, 5:239-251.
17. Murry T, Woodson GE: Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice 1995, 9:460-465.
18. Lee L, Daughton S, Scheer S, et al.: Use of acupuncture for the treatment of spasmodic dysphonia: a preliminary investigation. J Voice 2003, 17:411-424.
19. Hallett M: How does botulinum toxin work? Ann Neurol 2000, 48:7-8.
20. de Paiva A, Meunier FA, Molgo J, et al.: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999, 96:3200-3205.
21. Byrnes ML, Thickbroom GW, Wilson SA, et al.: The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 1998, 121:977-988.
22. Gilio F, Curra A, Lorenzano C, et al.: Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 2000, 48:20-26.
23. Bielamowicz S, Ludlow CL: Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Ann Otol Rhinol Laryngol 2000, 109:194-203.
24. Hogikyan ND, Wodchis WP, Spak C, Kileny PR: Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001, 15:57586.
25. Rubin AD, Wodchis WP, Spak C, et al.: Longitudinal effects of Botox injections on Voice-Related Quality of Life (V-RQOL) for patients with adductory spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2004, 130:415-420. This paper, together with Rubin et al, below, presents a thorough summary of patient-perceived benefit from BTX and offers as good a benchmark as any available for new therapy to exceed.
26. Tisch SH, Brake HM, Law M, et al.: Spasmodic dysphonia: clinical features and effects of botulinum therapy in 169 patients: an Australian experience. J Clin Neurosci 2003, 10:434-438.
27. Benninger MS, Gardner G, Grywalski C: Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2001, 127:1083-1085.
28. Langeveld TP, vanRossum M, Houtman EH, et al.: Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Ann Otol Rhinol Laryngol 2001, 110:627-634.
29. Courey MS, Garrett CG, Billante CR, et al.: Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol 2000, 109:819-822.
30. Boutsen F, Cannito MP, Taylor M, Bender B: Botox treatment of spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res 2002, 45:469-481.
31. Bielamowicz S, Stager SV, Badillo A, Godlewski A: Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice 2002, 16:117-123.
32. Sulica L, Blitzer A: Botulinum toxin treatment of spasmodic dysphonia. Op Tech Otolaryngol Head Neck Surg 2004, 15:76-80. A review and description of injection techniques, toxin dosages, and other details of treatment, with injection diagrams.
33. Pearson EJ, Sapienza CM: Historical approaches to the treatment of adductor-type spasmodic dysphonia (ADSD): review and tutorial. NeuroRehabilitation 2003, 18:325-338. A thorough and indispensable survey of the evolution of treatment for adductor spasmodic dysphonia over the past 30 years. The extensive bibliography is a useful resource.
34. Ludlow CL, Naunton RF, Fujita M, Sedory SE: Spasmodic dysphonia: botulinum toxin injection after recurrent laryngeal nerve surgery. Otolaryngol Head Neck Surg 1990, 102:122-131.
35. Sulica L, Blitzer A, Brin MF, Stewart CF: Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section. Ann Otol Rhinol Laryngol 2003, 112:499-505.
36. Berke GS, Blackwell KE, Gerratt BR, et al.: Selective laryngeal adductor denervation-reinnervation: a new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1999, 108:227-231.
37. Berke GS, Blumin JH: Spasmodic dysphonia: therapeutic options. Curr Opin Otolaryngol Head Neck Surg 2000, 8:509-513.
38. Allegretto M, Morrison M, Rammage L, Lau DP: Selective denervation:reinnervation for the control of adductor spasmodic dysphonia. J Otolaryngol 2003, 32:185-189. Duplication of the results of Berke et al. (Ann Otol Rhinol Laryngol 1999, 108:227-231), using the selective denervation operation.
39. Shaw GY, Sechtem PR, Rideout B: Posterior cricoarytenoid myoplasty with medialization thyroplasty in the management of refractory abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2003, 112:303-306.
40. Isshiki N, Tsuji DH, Yamamoto Y, Iikuza Y: Midline lateralization thyroplasty for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2000, 109:187-193.
41. Isshiki N, Haji T, Yamamoto Y, Mahieu HF: Thyroplasty for adductor spasmodic dysphonia: further experiences. Laryngoscope 2001, 111:615-621.
42. Bielamowicz S, Squire S, Bidus K, Ludlow CL: Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2001, 110:406-412.
43. Ozelius LJ, Hewett JW, Page C: The early-onset torsion dystonia gene (DYT-1) encodes an ATP-binding protein. Nat Genet 1997, 17:40-48.
44. Klein C, Brin MF, deLeon D: De novo mutations in the DYT1 gene in two non-Jewish patients with early-onset dystonia. Hum Mol Genet 1998, 7:1133-1136.
45. Walker RH, Shashidhran P: Developments in the molecular biology of DYT1 dystonia. Mov Disord 2003, 18:1102-1107. An essential summary of the current state of knowledge regarding the genetics of dystonia, the foundation from which further advances are likely to spring.